Universal API Implementation Guide
1.1.20 - ci-build
Universal API Implementation Guide - Local Development build (v1.1.20) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
IMPORTANT: UAPI - GPF Prescriber Form Changes
| Available in Test Environment | Product | LinkId | Text | Prescriber Form Version valid until: | Comments |
|---|---|---|---|---|---|
| Yes | All Products | "linkId": "ins-denial-reason" | "Denial reason (or attach copy of denial letter):" | 3/31/2026 (v5) | Previously included in Step 1 |
| Yes | All Products | "linkId": "ins-denial-date" | "For insurance denials, provide denial date:" | 3/31/2026 (v5) | Previously included in Step 1 |
| Available in Test Environment | Product | linkId | Text | Section on GPF form | GPF Prescriber Form Version | Comments |
|---|---|---|---|---|---|---|
| Yes | All Products | "linkId": "sot-hcp-affiliate" | "Is the third-party site of treatment affiliated with the same health system as the prescriber?" | Step 4 | 1/1/2026 (v6) | |
| Yes | All Products | "linkId": "has-insurance" | "Does the patient have any health insurance?" | Step 2 | 1/1/2026 (v6) | |
| Yes | All Products | "linkId": "denied-coverage" | "If insured, has the patient's insurance denied coverage for this medication?" | Step 2 | 1/1/2026 (v6) | include this linkId in FHIR bundle if patient is insured |
The following GPF questions will not be required to be answered as Genentech will automatically populate on your behalf:
| Product | Text | Section on GPF form | Comments |
|---|---|---|---|
| All Products | "Are copies of all insurance card(s) attached?" | Step 2 | We will automatically populate "NO" on GPF form |
| All Products | "Are insurance denial letter(s) and other documentation attached?" | Step 2 | We will automatically answer "NO" on GPF form |
(1) Include linkId: "site-of-treatment-2" questionnaire in bundle.
{
"linkId" : "site-of-treatment-2",
"text" : "Third-party Site of Treatment",
"answer" : [
{
"valueReference" : {
"reference" : "urn:uuid:45cf0b29-8c1d-4882-91e1-00bc28c06a52", <----- The uuid of the Organization resource for the SOT
"type" : "Organization"
}
}
]
},
(2) Include an Organization resource for the Site of Treatment where Organization.type.coding.code = other (partial sample below).
Example of SOT organization resource
{
"resourceType" : "Organization",
"id" : "45cf0b29-8c1d-4882-91e1-00bc28c06a52",
"meta" : {
"profile" : [
"🔗", "https://fhir.developer.gene.com/StructureDefinition/uapi-organization"
]
},
"text" : {
"status" : "generated",
"div" : ""
},
"identifier" : [
{
"use" : "usual",
"system" : "http://SOT.com",
"value" : "SOT-001",
"assigner" : {
"display" : "Florida Hospital Orlando Infusion Center"
}
}
],
"type" : [
{
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/organization-type",
"code" : "other",
"display" : "Site of Treatment"
}
],
"text" : "Site of Treatment"
}
],
"name" : "FLORIDA HOSPITAL ORLANDO INFUSION CNTR"}
Questionnaires for Copay enrollments can be accessed by requesting Lunsumio Velo Copay questionnaire definitions from the Genentech FHIR Server.
URL to Copay Questionnaire endpoint (test): https://test-us-e1.apis.roche.com/pharma-cmg-copay-exp-test/v1/questionnaire?name=Copay Lunsumio
Velo
URL to Copay Questionnaire endpoint (stage): https://stage-us-e1.apis.roche.com/pharma-cmg-copay-exp-stage/v1/questionnaire?name=Copay Lunsumio Velo
URL to Copay Questionnaire endpoint (prod): https://prod-us-e1.apis.roche.com/pharma-cmg-copay-exp-prod/v1/questionnaire?name=Copay Lunsumio Velo
Refer to brandIds table on Copay Value Set page
FDA approved indications (ICD10 codes) can be found on the Access Solutions website for Lunsumio Velo
| Type | Release to Production | Available in QA (test) environment? | Product(s) impacted | linkId impacted (if applicable) | OLD | New | Comment |
|---|---|---|---|---|---|---|---|
| Addition | 2/6/2026 | Yes | Lunsumio Lunsumio Velo |
lunsumio-form-of-lunsumio lunsumio-velo-form-of-lunsumio |
- | Text: "Which form of LUNSUMIO are you taking?" "valueString": "Intravenous infusion (IV) for LUNSUMIO" "valueString": "Subcutaneous (SC) injection for LUNSUMIO VELO" |
same for both Lunsumio & Lunsumio Velo |
| Update | 2/6/2026 | Yes | Lunsumio | lunsumio-fda-approved-indications | Text: Is the patient using LUNSUMIO® (mosunetuzumab-axgb) for the following FDA-approved indication? LUNSUMIO is a prescription medicine used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments for their cancer. It is not known if LUNSUMIO is safe and effective in children. The conditional approval of LUNSUMIO is based on response rate. There are ongoing studies to establish how well the drug works. |
Is the patient using LUNSUMIO® (mosunetuzumab-axgb) or LUNSUMIO VELO™ (mosunetuzumab-axgb) for the following FDA-approved indication? Adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments for their cancer. It is not known if LUNSUMIO or LUNSUMIO VELO is safe and effective in children. The conditional approval of LUNSUMIO and LUNSUMIO VELO is based on response rate. There are ongoing studies to establish how well the drug works. |
|
| Add | 2/6/2026 | Yes | Lunsumio Velo | lunsumio-velo-fda-approved-indications | - | Is the patient using LUNSUMIO® (mosunetuzumab-axgb) or LUNSUMIO VELO™ (mosunetuzumab-axgb) for the following FDA-approved indication? Adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments for their cancer. It is not known if LUNSUMIO or LUNSUMIO VELO is safe and effective in children. The conditional approval of LUNSUMIO and LUNSUMIO VELO is based on response rate. There are ongoing studies to establish how well the drug works. |